A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.

Abstract

"Cancer-germline" genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in normal tissues. They encode shared tumor-specific antigens, which have been used in therapeutic vaccination trials of cancer patients. MAGE-6 is expressed in more than 70% of metastatic melanomas and more than 50% of carcinomas of the lung, esophagus, bladder, and head and neck. We report here the identification of a new MAGE-6 antigenic peptide, which is recognized by a tumor-specific cytolytic T lymphocyte clone isolated from a melanoma patient. The peptide, ISGGPRISY, corresponds to positions 293 to 301 of the MAGE-6 protein sequence and is presented by HLA-Cw1601 molecules.

• Authors: Valérie Vantomme, Pascale Boël, Etienne De Plaen, Thierry Boon, Pierre van der Bruggen
• Journal: Cancer immunity (Cancer Immun) Vol. 3 Pg. 17 (Dec 10 2003) ISSN: 1424-9634 [Electronic] United States
• PMID: 14664500 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antigens, Neoplasm
• MAGEA1 protein, human
• MAGEA6 protein, human
• Melanoma-Specific Antigens
• Neoplasm Proteins
• Oligopeptides

Topics

• Amino Acid Sequence
• Animals
• Antigens, Neoplasm (genetics, immunology)
• COS Cells
• Cell Line, Tumor
• Cytotoxicity, Immunologic (drug effects, immunology)
• Dose-Response Relationship, Drug
• Female
• Humans
• Melanoma (immunology, pathology)
• Melanoma-Specific Antigens
• Molecular Sequence Data
• Neoplasm Proteins (genetics, immunology)
• Oligopeptides (genetics, immunology, pharmacology)
• T-Lymphocytes, Cytotoxic (immunology)